drugset
drugset / Trial / NCT05797948

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT05797948 ↗

Unknown 20 enrolled The First Affiliated Hospital of Soochow University
NaSingle-groupOpen-labelTreatment

Summary

This study intends to use Obinutuzumab, Zanubrutinib, and Lenalidomide sequential CD19/CD22 CAR-T in the treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma patients. The main purpose of this study is to explore a new treatment mode for R/R B-NHL patients and observe the efficacy and safety of this treatment regimen.

Timeline

Start
2022-07-01
Primary completion
2024-06-30
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CD19/CD22 CAR-T Cell therapy 1e+07 cells/kg Other
Subject Lenalidomide Other / unclassified 25 mg Oral
Subject Obinutuzumab Monoclonal antibody 1000 mg Intravenous
Subject Zanubrutinib Small molecule 160 mg Oral
Background Azacitidine Other / unclassified 100 mg Other
Background Cyclophosphamide Other / unclassified 300 mg/m2 Intravenous
Background Fludarabine Small molecule 300 mg/m2 Intravenous

Indications

B-cell non-Hodgkin lymphoma